'Precision psychiatry' company lines up $60M in quest for targeted depression drug
Alto Neuroscience reported data from one mid-stage study this month and started another, both using a biomarker to carry the right drug to the right person with depression.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Brain | Depression | Health Management | Neurology | Pharmaceuticals | Psychiatry | Study